XPW1
XPW1 is a potent and selective CDK9 inhibitor with excellent activity against clear cell renal cell carcinoma (ccRCC) and low toxicity[1].
Product Specifications
CAS Number
2700286-66-2
UNSPSC
12352005
Target
CDK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/xpw1.html
Purity
99.27
Solubility
DMSO : 31.25 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(N[C@H]1CC[C@H](NC2=NC=C(Cl)C(C3=NC(NCC4=CC=CC(F)=C4)=CC=C3)=C2)CC1)C5=CC=C(NC(/C=C/CN(C)C)=O)C=C5
Molecular Formula
C36H39ClFN7O2
Molecular Weight
656.19
References & Citations
[1]Kuang Z, et al. The novel CDK9 inhibitor, XPW1, alone and in combination with BRD4 inhibitor JQ1, for the treatment of clear cell renal cell carcinoma. Br J Cancer. 2023 Oct 26.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
